MedTrace Logo

Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer

NCT01783951 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 63

Last updated 2018-07-19

No results posted yet for this study

Summary

The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1 based chemotherapy for advanced gastric cancer.

Conditions

Interventions

BIOLOGICAL

DC-CIK

Patients will be receive DC-CIK cell therapy at days 15, 17 and 19 per cycle and received cycles of treatment once every 21 days.

DRUG

S-1

The dose of S-1 is determined according to the body surface area as follows: \<1.25 m2, 40 mg; 1.25 to \<1.5 m2, 50 mg; and ≥1.5 m2, 60 mg, given twice daily after meals for 14 days followed by 7 days rest.

DRUG

Cisplatin

Cisplatin is administered at 75 mg/m2 intravenously over 1 to 3 hours every 21 days.

Sponsors & Collaborators

  • Duke University

    collaborator OTHER

  • Geneplus-Beijing Co. Ltd.

    collaborator INDUSTRY

  • Capital Medical University

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-01
Primary Completion
2018-02-28
Completion
2018-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01783951 on ClinicalTrials.gov